6:07 AM ET
8-K
Investor Meeting
Nektar Therapeutics Investor Meeting
Nektar Therapeutics reaffirmed its financial guidance, stating that its current cash and marketable securities balance of $952.9 million is expected to fund operations into the third quarter of 2028. This runway is intended to support the company through the initial Phase 3 data readouts for its ZENITH AD trials in atopic dermatitis, expected in the summer of 2028.